BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...modulator for acute myelogenous leukemia patients undergoing hematopoietic stem cell transplantation.The group believes mocravimod, which Priothera Ltd....
Items per page:
1 - 1 of 1
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...modulator for acute myelogenous leukemia patients undergoing hematopoietic stem cell transplantation.The group believes mocravimod, which Priothera Ltd....
Items per page:
1 - 1 of 1